Maternal obesity alters fetal liver metabolism via placental molecular signals

https://www.news-medical.net/news/20260826/Maternal-obesity-alters-fetal-liver-metabolism-via-placental-molecular-signals.aspx A mother's obesity during pregnancy may send molecular signals across the placenta that permanently alter her son's liver metabolism, according to a new study in mice published in Nature Communications. The research traces this effect to a maternal sEV–miRNA–epigenetic axis that links fetal liver programming to long-term metabolic health.

Gut bacteria may send different biological signals in Parkinson’s disease

https://www.news-medical.net/news/20260826/Gut-bacteria-may-send-different-biological-signals-in-Parkinsone28099s-disease.aspx A new study from the University of Oulu suggests that gut bacteria may send different biological signals in Parkinson’s disease. The findings add to growing evidence that changes in the gut could be linked to Parkinson’s disease and may eventually help researchers identify new underlying mechanisms for the condition.

Study tracks global patterns and socioeconomic inequalities in the burden of breast cancer

https://www.news-medical.net/news/20260826/Study-tracks-global-patterns-and-socioeconomic-inequalities-in-the-burden-of-breast-cancer.aspx Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death among women globally, accounting for nearly 2.3 million new cases and 670,000 deaths in 2022 alone. While traditional metrics like annual incidence rates provide a snapshot of disease burden, they do not capture the cumulative probability that an individual will face breast cancer over their entire lifetime. Moreover, the interplay of reproductive patterns, lifestyle factors, screening access, and treatment quality varies enormously across regions with different levels of economic development. Based on these challenges, there is a clear need for a more intuitive, comparable indicator that accounts for life expectancy and competing mortality risks to guide global cancer control strategies

Why living to 100 may depend on far more than diet and exercise

https://www.news-medical.net/news/20260825/Why-living-to-100-may-depend-on-far-more-than-diet-and-exercise.aspx From diet and exercise to social ties and genetics, researchers examined why the habits linked to healthier aging may not fully explain who survives to 100. In a recent critical narrative review published in the journal Minerva Medica, researchers synthesized multidisciplinary evidence investigating whether human longevity can be engineered through behavioral modifications and standardized lifestyle “recipes”. The review aimed to assess the scientific validity of the increasingly pervasive commercial and media narrative associating human longevity with lifestyle choices.

Ear Microbiome Composition and Its Role in Health and Disease

https://www.news-medical.net/health/Ear-Microbiome-Composition-and-Its-Role-in-Health-and-Disease.aspx From protective cerumen and resident microbes to striking shifts in bacterial and fungal communities, emerging sequencing research is uncovering a complex microbial ecosystem within the ear that may reshape our understanding of ear health and disease.

Lasers and Math Can Help Doctors Deliver Just the Right Amount of Medicine August 26, 2026 By: Henry Nonnemaker

https://www.nist.gov/blogs/taking-measure/lasers-and-math-can-help-doctors-deliver-just-right-amount-medicine When doctors need to deliver precise doses of medicine on a strict schedule, they often administer it intravenously. Intravenous drug delivery methods need to carefully control the flow of medicine into a patient. Knowing the medicine’s flow rate — or the volume of fluid flowing into the patient each second or minute — is crucial to delivering the right amount of medicine at the right time. Surprisingly, the correct amount is sometimes not very much at all. Imagine a one-liter bottle divided up into a billion parts. One of those parts is a nanoliter. Doctors may only need a handful of nanoliters of fluid to flow each minute.

Resilience and well-being as positive determinants of mental health in Israel amid challenges Rabab Awad* [1]ORCID iD , Alon Zamir [2,3]ORCID iD , Liat Ayalon [1] + +...

https://www.academia.edu/2997-9196/3/2/10.20935/MHealthWellB8346 The State of Israel, with its unique social fabric, provides a distinctive context for examining resilience and well-being as positive indicators of mental health. Although a growing body of research has addressed these issues, existing knowledge remains fragmented and lacks an integrative, multilevel synthesis. This narrative review synthesizes empirical research conducted in Israel since 2000 on resilience and well-being in the contexts of war and armed conflict, immigration waves, and the COVID-19 pandemic. The review is guided by a multidimensional analytical framework comprising two axes. The first examines resilience and well-being at the macro, meso, and micro levels, emphasizing societal-, institutional-, community-, and individual-level factors that potentially enhance or maintain resilience and well-being in the face of these challenges. The second compares findings across population groups, including ethnic groups, age cohorts, essential workers, and other vulnerable populations in Israeli society. The findings indicate that resilience and well-being vary across the individual, community, and societal levels and across different societal challenges, reflecting the interaction of personal, relational, and structural factors under prolonged stress. Overall, resilience and well-being emerge as key positive dimensions of mental health, highlighting the need for context-sensitive and multilevel approaches to strengthen adaptive functioning during challenging times. https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav

FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia (wAIHA) by Madaline Spencer| Published on: Aug 26, 2026

https://checkrare.com/fda-approves-first-treatment-for-warm-autoimmune-hemolytic-anemia-waiha/

The far-reaching effects of wildfire smoke The Lancet Respiratory Medicine +... ++

The far-reaching effects of wildfire smoke The Lancet Respiratory Medicine https://www.thelancet.com/journals/lanres/issue/vol14no9/PIIS2213-2600(26)X2008-2 Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial Prof Zhengbo Song, MDa Send email to songzb@zjcc.org.cn ∙ Prof Xingya Li, MDb ∙ Rongbo Lin, MDc ∙ Huaqiu Shi, BSd ∙ Yuan Yuan, MSce ∙ Ying Liu, MDf ∙ et al. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00142-6/abstract?dgcid=raven_jbs_etoc_feature_lanres Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial Prof Kate Leslie, MDa,b Send email to kate.leslie@mh.org.au ∙ Jai N Darvall, PhDa,b ∙ Prof Matthew T V Chan, PhDc ∙ Prof Philip J Peyton, PhDa,d ∙ Prof Paul S Myles, DSce,f ∙ Prof Tomás B Corcoran, MDg ∙ et al https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00158-X/fulltext?dgcid=raven_jbs_etoc_feature_lanres

Oculomics and the search for brain biomarkers The Lancet Digital Health +... ++

Oculomics and the search for brain biomarkers The Lancet Digital Health https://www.thelancet.com/journals/landig/issue/vol8no8/PIIS2589-7500(26)X2008-8 Effectiveness of app-based interventions for glucose management, cardiometabolic and mental health, and related risk factors: an umbrella review with meta-analysis Maria F Vasiloglou, PhDa Send email to maria.vasiloglou@rd.nestle.com ∙ Evangelia Kotzakioulafi, MSca ∙ Fabio Mainardi, PhDa ∙ Mavra Ahmed, PhDb,c ∙ Amanda E Staiano, PhDd ∙ Eirini Dimidi, PhDe ∙ et al. https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00032-4/fulltext?dgcid=raven_jbs_etoc_feature_landig Prediction of structural glaucoma progression from baseline fundus photographs using deep learning: a retrospective multicentre study Ruben Hemelings, PhDa,b,c Send email to ruben.hemelings@seri.com.sg ∙ Damon W Wong, PhDa,b ∙ Jacqueline Chua, PhDa,d ∙ Jan Van Eijgen, PhDc,e ∙ João Barbosa-Breda, PhDc,f,g ∙ Adèle Ehongo, PhDh ∙ et al. https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00055-5/fulltext?dgcid=raven_jbs_etoc_feature_landig

FDA Approves First Drug for Warm Autoimmune Hemolytic Anemia

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia?utm_medium=email&utm_source=govdelivery FDA Approves Imaavy (nipocalimab-aahu) for Warm Autoimmune Hemolytic Anemia The U.S. Food and Drug Administration has approved a new indication for Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older with inadequate response to corticosteroids or immunosuppressive therapy. Imaavy was previously approved for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. wAIHA is a condition in which the immune system mistakenly targets and destroys the body's own red blood cells, leading to anemia that can range from mild to severe and life-threatening. Like gMG, wAIHA is driven by harmful IgG autoantibodies. Imaavy is a targeted therapy that works by blocking a protein in the body called the neonatal Fc receptor (FcRn), which normally keeps those disease-causing antibodies circulating in the blood. By blocking this receptor, Imaavy speeds up the removal of those harmful antibodies, helping to reduce the damage they cause. Imaavy is administered as an intravenous infusion. The approval was granted to Janssen Biotech, Inc. For more information visit: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia

Navigating the FDA Bayesian Draft Guidance: Design, Analysis, and Review Considerations October 14, 2026

https://www.fda.gov/drugs/news-events-human-drugs/navigating-fda-bayesian-draft-guidance-design-analysis-and-review-considerations-10142026?utm_medium=email&utm_source=govdelivery Join SBIA for its Navigating the FDA Bayesian Draft Guidance: Design, Analysis, and Review Considerations! This webinar will provide an in-depth overview of FDA's January 2026 draft guidance on the use of Bayesian methodology in clinical trials of drug and biological products, a PDUFA VII commitment, and its implications for trial design and analysis. You should attend if you’re a clinical trial, regulatory science and regulatory affairs professional working on clinical trials and studies where Bayesian methods can potentially be used as an alternative statistical approach. Such uses are most beneficial in settings where it is appropriate to leverage information from previous studies or use adaptive designs. The most common settings include pediatric and rare disease trials. FDA experts will walk through guidance topics including success criteria and operating characteristics in Bayesian trials, considerations for prior distributions, missing data and estimands in a Bayesian framework, documentation and reporting expectations, and more. If you have comments or questions, contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.

The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations Authors: Neal D. Shore, MD, FACS; Sarah Caulfield, PharmD, BCOP; Rana R. McKay, MD, FASCO

https://www.medscape.org/viewarticle/new-era-mhspc-treatment-evaluating-emerging-doublet-and-2026a1000kt7?page=1&src=mkmcmr_driv_32025_mscpedu_461680.07_ace_launch&uac=148436CN

FDA READI-Home Innovation Challenge: Reducing Readmissions through Device Innovation for the Home

https://www.fda.gov/medical-devices/home-health-care-hub/fda-readi-home-innovation-challenge-reducing-readmissions-through-device-innovation-home?utm_medium=email&utm_source=govdelivery FDA Announces Initial Participants Selected for READI-Home Innovation Challenge The FDA has selected initial participants to advance to the interaction phase of the READI-Home Innovation Challenge, an effort to accelerate patient access to home use medical device technologies that may help reduce hospital readmissions. Participants selected to advance to the interaction phase of the Innovation Challenge will receive: Early engagement with the FDA through sprint discussions. More frequent interactions and feedback to help refine device design and/or relevant testing for home use indications. An opportunity to demonstrate their technology at the FDA’s research facilities. These selections represent an important step in advancing innovative technologies for care at home after an acute hospital stay. The FDA intends to update the list as additional participants are selected. Submissions will continue to be accepted through September 30, 2026. Questions? If you have questions about this Innovation Challenge, please refer to our Frequently Asked Questions or email HealthHomeHub@fda.hhs.gov with the subject line “READI-Home Innovation Challenge Inquiry.”

Bacteria share proteins to survive antibiotics

Bacteria share proteins to survive antibiotics At a Glance Researchers found that some bacteria share proteins that help others survive antibiotics. The study suggests a novel approach that may help treat persistent bacterial infections. https://www.nih.gov/news-events/nih-research-matters/bacteria-share-proteins-survive-antibiotics

Immune cells cross blood-brain barrier during human aging

Immune cells cross blood-brain barrier during human aging At a Glance Researchers found that some of the brain’s immune cells are replaced by immune cells from bone marrow as people age. The findings suggest that scientists might one day be able to use immune cells born outside the brain to deliver therapies for brain disorders. https://www.nih.gov/news-events/nih-research-matters/immune-cells-cross-blood-brain-barrier-during-human-aging

DNA organization changes in Alzheimer’s disease, aging

DNA organization changes in Alzheimer’s disease, aging At a Glance New research showed the 3D organization of DNA in cells changes in Alzheimer’s disease and aging. The results suggest the changes may contribute to altered gene activity observed in Alzheimer’s and aging. https://www.nih.gov/news-events/nih-research-matters/dna-organization-changes-alzheimers-disease-aging

Coating stops tooth decay in children

Coating stops tooth decay in children At a Glance A clinical trial found that a topical treatment called silver diamine fluoride stops cavities in young children from getting worse. The simple treatment could prevent surgery and other serious consequences for children with severe tooth decay. https://www.nih.gov/news-events/nih-research-matters/coating-stops-tooth-decay-children

Dementia-free years may decrease with smoking, hypertension, and diabetes

Dementia-free years may decrease with smoking, hypertension, and diabetes At a Glance Researchers found that smoking, high blood pressure, and diabetes in midlife lower the number of years a person is likely to live without dementia. The findings could help guide behavior and lifestyle changes to prevent dementia. https://www.nih.gov/news-events/nih-research-matters/dementia-free-years-may-decrease-smoking-hypertension-diabetes

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

https://clinicaltrials.gov/study/NCT05406583?utm_medium=email&utm_source=govdelivery FDA Approves Drug to Treat HIV Infection in Newborns The U.S. Food and Drug Administration (FDA) has approved Tivicay PD tablets for oral suspension (dolutegravir) to treat HIV infection in babies from birth up to four weeks weighing at least 2 kg, in combination with other antiretroviral agents. Tivicay and Tivicay PD were previously approved for adults and children older than four weeks. Condition HIV (human immunodeficiency virus) is a virus that attacks the body's immune system, increasing the chances of developing serious infections or cancer and without treatment can lead to AIDS (acquired immunodeficiency syndrome). There is no cure for HIV, but prevention and treatment options are available. Data Supporting Tivicay PD in Newborns Data from the IMPAACT 2023 study and pharmacokinetic modeling data supported the application. In this study (NCT05406583), 48 newborns exposed to HIV 1 and weighing at least 2 kg received Tivicay PD from birth for up to six weeks, in combination with standard-of-care antiretroviral medications to prevent mother-to-child HIV transmission. The newborns were followed for 16 weeks. Results showed the drug levels of Tivicay PD in newborns were similar to those associated with efficacy in adults. The drug’s safety profile in newborns was also similar to that observed in older pediatric and adult patients. Safety Information Patients should not receive Tivicay or Tivicay PD if they had previous allergic reactions to the drug, or if they are also receiving dofetilide. Serious allergic reactions have been reported. Patients should be monitored for liver damage. Immune resconstitution syndrome has been reported in patients treated with combination antiretroviral therapy. Taking Tivicay or Tivicay PD with certain other medications may cause the drug to stop working against HIV or lead to serious side effects. Patients or their caregivers should tell their healthcare provider about all medications they are taking before starting Tivicay or Tivicay PD. Tivicay tablets and Tivicay PD tablets for oral suspension are not substitutable on a milligram-per-milligram basis. Designations Tivicay PD received priority review for this population.

Uncovering how obesity leads to Alzheimer’s disease It’s long been recognized that obesity in midlife significantly raises the risk of Alzheimer’s disease. A new study shows the biological mechanisms that contribute to pathogenesis. Written byAllison Whitten, PhD

Uncovering how obesity leads to Alzheimer’s disease It’s long been recognized that obesity in midlife significantly raises the risk of Alzheimer’s disease. A new study shows the biological mechanisms that contribute to pathogenesis. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/uncovering-how-obesity-leads-to-alzheimer-s-disease-17179?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--Ma_mRbio0_Tb9p1to7Y9ISzL1XmEa_xhjnMoEFiDVDEmPIT-1hTcTtKZhzWoSY1eBl32o4-zZ5EsBrrMU2kBmqtBvTQ&_hsmi=434969664&utm_content=434969664&utm_source=hs_email The biggest risk factor in the development of Alzheimer’s disease (AD) is one that can’t be controlled: the act of aging itself. But there are other risk factors that lay the groundwork for the disease earlier in life that can be changed — like obesity during midlife. The presence of obesity in middle age can mean up to a 74 percent increased risk of developing dementia, clearly signaling a key relationship between excess adipose tissue and neurodegeneration in the brain. Yet, the biological mechanisms linking the two have remained a mystery.

Can the healthcare system catch up to GLP-1 drug use? Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results. Written byBree Foster, PhD

Can the healthcare system catch up to GLP-1 drug use? Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results. Written byBree Foster, PhD https://www.drugdiscoverynews.com/can-the-healthcare-system-catch-up-to-glp-1-drug-use-17108?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9GYVEyXaLMBMj7Xa8j5E3MeIhFDq5KR_VGZf5UT9yQSdPvyz5GI5HW7ZLuuFxg1Sin_w1O_cnWryV1P2aYsWqEITplEA&_hsmi=434969664&utm_content=434969664&utm_source=hs_email When GLP-1 drugs first entered clinical practice nearly two decades ago, few could have predicted how quickly they would escape the confines of endocrinology and enter everyday conversation. Today, medications like Ozempic and Wegovy are discussed not just in clinics and conferences, but on social media, red carpets, and group chats — often framed as lifestyle enhancers rather than powerful, lifelong medications.

An old small molecule drug could fight obesity and keep lean muscle First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss. Written byAllison Whitten, PhD

An old small molecule drug could fight obesity and keep lean muscle First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/an-old-small-molecule-drug-could-fight-obesity-and-keep-lean-muscle-17474?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_el91H-YOBZXtKN3rSW1QsRWKG4f_FOW09aYVw97dGYSA0f5DJkZv1qln-AvNYlBOfC8ODfPOF7vQ61WKcRJhKa7Wztw&_hsmi=434969664&utm_content=434969664&utm_source=hs_email Losing weight can happen via two paths: eating less, or spending more energy. Today’s blockbuster GLP-1 drugs are well-known for their ability to help people eat less, but finding drugs that increase energy expenditure could add another effective option to treat obesity and related metabolic disorders.

FDA drafts roadmap for regulating generative AI medical devices STAT News | August 25, 2026

https://geneticliteracyproject.org/2026/08/25/fda-drafts-roadmap-for-regulating-generative-ai-medical-devices/ The FDA is drafting a first-ever policy roadmap for regulating medical devices powered by generative AI, according to STAT News reporter Mario Aguilar. “Our goal is formal policy guidance,” said Rick Abramson, director of the FDA’s Digital Health Center of Excellence, describing the discussion paper the agency recently released.

CRISPR-edited tomatoes could deliver dramatically higher cold-season yields The Hebrew University of Jerusalem | August 25, 2026

https://geneticliteracyproject.org/2026/08/25/crispr-edited-tomatoes-could-deliver-dramatically-higher-cold-season-yields/ Researchers identify a genetic mechanism that coordinates flower development and fruit formation, paving the way toward tomato varieties with more reliable winter harvests.

FDA-approved mRNA flu vaccine signals future for RNA therapeutics Li Li | August 25, 2026

https://geneticliteracyproject.org/2026/08/25/fda-approved-mrna-flu-vaccine-signals-future-for-rna-therapeutics/ Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often not directly transferable to another.

The story behind Moderna’s cancer vaccine miracle Wall Street Journal | August 25, 2026

https://geneticliteracyproject.org/2026/08/25/the-story-behind-modernas-cancer-vaccine-miracle/ A personalized mRNA shot for melanoma just did something no cancer vaccine has done before. As The Wall Street Journal’s Alex Janin reports, the company’s personalized mRNA cancer vaccine, intismeran autogene, succeeded in a Phase 3 trial for high-risk melanoma patients — the first personalized mRNA cancer therapy to hit its mark in a late-stage study.

What’s the political and health battle over GRAS–ingredients ‘Generally Recognized as Safe’ Chuck Dinerstein | August 25, 2026

https://geneticliteracyproject.org/2026/08/25/whats-the-political-and-health-battle-over-gras-ingredients-generally-recognized-as-safe/ Behind every significant advance in US food safety lies a public health disaster that forced Congress to act. A regulatory carve-out, the GRAS loophole, a long-standing exception intended for harmless pantry staples, remains a pathway that allows food and supplement companies decide for themselves whether new ingredients are safe. The FDA is once again under pressure to rein in GRAS. At stake is how much the public should trust an invisible self-policing system and the forces calling for change.

Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks by Madaline Spencer| Published on: Jun 25, 2026

https://checkrare.com/oral-deucrictibant-for-on-demand-treatment-of-hereditary-angioedema-attacks/

FDA Approves Multiple Myeloma Treatment, Denies Neuroendocrine Tumors Treatment by CheckRare Staff| Published on: Aug 20, 2026

FDA Approves Multiple Myeloma Treatment, Denies Neuroendocrine Tumors Treatment by CheckRare Staff| Published on: Aug 20, 2026 https://checkrare.com/fda-approves-multiple-myeloma-treatment-denies-neuroendocrine-tumors-treatment/

Addressing Patient Experiences With IgA Nephropathy by Madaline Spencer| Published on: Aug 24, 2026

Addressing Patient Experiences With IgA Nephropathy by Madaline Spencer| Published on: Aug 24, 2026 Gaia Coppock, MD, Nephrologist and Associate Professor of Clinical Medicine at the University of Pennsylvania, discusses patient experiences with IgA nephropathy (IgAN). https://checkrare.com/addressing-patient-experiences-with-iga-nephropathy/

Cancer screening guidelines need to address long-term care facilities I’m a cancer epidemiologist, and my aunt’s recent passing from stage 4 breast cancer led me to reflect on guidelines

https://www.statnews.com/2026/08/25/cancer-screening-guidelines-long-term-care-facilities/ By Kim JohnsonAug. 25, 2026 Johnson is a cancer epidemiologist and professor at Washington University in St. Louis in the Brown School of Social Work.

Certain Blood Transfusions Put Patients At Risk Of Experiencing Symptoms of Alpha-Gal Syndrome, Study Finds +...

Certain Blood Transfusions Put Patients At Risk Of Experiencing Symptoms of Alpha-Gal Syndrome, Study Finds MedPage Today reported that in regions of the U.S. with a high prevalence of tick-induced alpha-gal syndrome (AGS), researchers found that people with type O blood who received B or AB platelet or plasma units were nearly four times more likely to have an allergic transfusion reaction compared with those who received O units. Researchers said the findings would likely lead to a change in transfusion practices. https://kffhealthnews.org/morning-breakout/pharma-and-tech-082526/ Study: At Least 25% Of NFL Players Could End Up With Brain Disease Researchers noted that the rate of actual chronic traumatic encephalopathy, or CTE, is likely higher given that not all players' brains were tested after they died. “I bet the real number is a lot bigger,” said former Tampa Bay Buccaneers center Randy Grimes, who lost two teammates who were found to have had CTE. Scientists hope this information leads to reforms to minimize the disease's occurrence. https://kffhealthnews.org/morning-briefing/tuesday-august-25-2026/

Dr. Wendy Weber to serve as director of the National Center for Complementary and Integrative Health + +... +... +... +...

Dr. Wendy Weber to serve as director of the National Center for Complementary and Integrative Health Dr. Wendy Weber Today, National Institutes of Health (NIH) Director Jay Bhattacharya, M.D., Ph.D., announced that Wendy Weber, N.D., Ph.D., has been selected to serve as director of NIH’s National Center for Complementary and Integrative Health (NCCIH). Since October 2025, Dr. Weber has provided scientific leadership and strategic counsel and contributed to budget oversight to NCCIH as acting deputy director. She began her new role on August 23, 2026. https://www.nih.gov/news-events/news-releases/dr-wendy-weber-serve-director-national-center-complementary-integrative-health The National Center for Complementary and Integrative Health (NCCIH) is pleased to announce the selection of Wendy J. Weber, N.D., Ph.D., M.P.H., as the next director of NCCIH, effective August 23, 2026. “I am genuinely honored to be stepping into this role, and I'm excited about what's ahead,” said Dr. Weber. “I am so excited to take on the leadership for the Center and bring us into the next chapter.” Dr. Weber has been an instrumental part of NCCIH over the last 17 years. Since October 2025, she served as acting deputy director of NCCIH, providing scientific leadership and strategic counsel during a period of transition. Before this, Dr. Weber served as the branch chief for the Clinical Research in Complementary and Integrative Health Branch in NCCIH’s Division of Extramural Research and was responsible for the oversight of NCCIH-supported clinical trials. As NCCIH director, Dr. Weber will remain committed to scientific rigor and advancing NCCIH’s programs in pain research and whole person health. “Her combination of clinical training in naturopathic medicine and doctoral-level research training in epidemiology gives Dr. Weber a rare dual perspective, bridging complementary health practice with rigorous scientific methodology,” said National Institutes of Health (NIH) Director Jay Bhattacharya, M.D., Ph.D. Dr. Weber has held a series of increasingly senior leadership roles at NCCIH and brings extensive experience with NIH and NCCIH programs, including the Pain Management Collaboratory, Helping to End Addiction Long-term® Initiative, Science of Behavior Change, and Pragmatic Trials Collaboratory. Dr. Weber earned an M.P.H. and Ph.D. in epidemiology from the University of Washington and a doctorate of naturopathic medicine (N.D.) from Bastyr University. Prior to joining NIH, Dr. Weber was a clinician-scientist and associate professor at Bastyr University. As an NCCIH-funded researcher, she was the first naturopathic physician to receive an NIH career development award, which supported her work on botanical interventions. The Pain Management Collaboratory (PMC) Closing the Gap between Science and Clinical Practice for Pain Management https://painmanagementcollaboratory.org/ The Helping to End Addiction Long-term® Initiative The NIH HEAL Initiative® is an NIH-wide effort to improve prevention and treatment strategies for opioid misuse and addiction and to enhance pain management.​ https://www.nih.gov/heal Science of Behavior Change (SOBC) https://commonfund.nih.gov/behaviorchange The Science of Behavior Change (SOBC) program used a systematic approach to improve our understanding of the underlying mechanisms that would drive behavior change. Unhealthful behaviors—such as smoking, drug and alcohol abuse, overeating, and a sedentary lifestyle—contribute to negative health outcomes and common diseases. Effective approaches to adopting and maintaining healthy behaviors remain few. Though some interventions may lead to changes in behavior in some people, scientists rarely know how or why they work. SOBC researchers used a scientific method to investigate how and why people adopt and sustain healthy behaviors. SOBC brought together scientists from various disciplines, spanning basic and translational science across different health-related behaviors, to explore how a focus on the mechanisms of behavior change in the development of behavior change interventions could reliably improve health outcomes. Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials https://rethinkingclinicaltrials.org/ Welcome to the Living Textbook of pragmatic clinical trials, a collection of knowledge from the NIH Pragmatic Trials Collaboratory. Pragmatic clinical trials present an opportunity to efficiently generate high-quality evidence to inform medical decision-making. However, these trials pose different challenges than traditional clinical trials. The Living Textbook reflects a collection of special considerations and best practices in the design, conduct, and reporting of pragmatic clinical trials.

Beyond cancer: The Right to be Forgotten The Lancet Oncology ++... ++

Beyond cancer: The Right to be Forgotten The Lancet Oncology https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00399-2/fulltext?dgcid=raven_jbs_etoc_email Sep 2026 Volume 27Number 9p1057-1192, e403-e439 https://www.thelancet.com/journals/lanonc/issue/vol27no9/PIIS1470-2045(26)X2008-3 Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus Prof Jean-Michel Hannoun-Levi, MD PhDa Send email to jean-michel.hannoun-levi@nice.unicancer.fr ∙ Prof Julie A Margenthaler, MDb ∙ Bethany Anderson, MD PhDc ∙ Rosa Di Micco, MD PhDd ∙ Prof Douglas W Arthur, MDe ∙ Prof Marianne Aznar, PhDf ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00177-4/abstract?dgcid=raven_jbs_etoc_feature_lanonc Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study Prof Masatoshi Kudo, MD PhDa,* Send email to mkudo@med.kindai.ac.jp ∙ Prof Ghassan K Abou-Alfa, MDb,c,d,* Send email to abou-alg@mskcc.org ∙ Prof Zhenggang Ren, MDe ∙ Prof Jeong Heo, MD PhDf ∙ Prof Riccardo Lencioni, MDg ∙ Yasuaki Arai, MDh ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00278-0/abstract?dgcid=raven_jbs_etoc_feature_lanonc

Major brain changes that occur around age 50 could impact dementia risk By Melissa Rudy Fox News Published August 25, 2026 7:00am EDT +...

Major brain changes that occur around age 50 could impact dementia risk https://www.foxnews.com/health Microglia decline after age 50 as inflammatory blood-derived immune cells infiltrate the hippocampus, potentially driving neuroinflammation and dementia. Protective immune cells begin to decline and are increasingly replaced by more inflammatory cells in midlife, study finds Melissa Rudy By Melissa Rudy Fox News Published August 25, 2026 7:00am EDT https://www.foxnews.com/health/major-brain-changes-occur-around-age-50-could-impact-dementia-risk

Trial Uncertainties Rarely Make It Into Cancer Guidelines

https://www.medscape.com/viewarticle/trial-uncertainties-rarely-make-it-cancer-guidelines-2026a1000qe0?ecd=WNL_trdalrt_pos1_ous_260825_etid8629818&uac=148436CN&impID=8629818

US Cancer Trials Heavily Favor Single Drugs Over Care Issues Medscape Medical News ++++ ++++

US Cancer Trials Heavily Favor Single Drugs Over Care Issues Medscape Medical News 26 minutes ago US Cancer Trials Heavily Favor Single Drugs Over Care Issues Ernie Mundell https://www.medscape.com/viewarticle/us-cancer-trials-heavily-favor-single-drugs-over-care-issues-2026a1000tjt?src= Ruxolitinib Reduces Acute GVHD in Transplant Patients Medscape Medical News 1 hour ago Low-Dose Ruxolitinib Reduces Acute GVHD After Haploidentical Stem Cell Transplantation August 25, 2026 https://www.medscape.com/viewarticle/low-dose-ruxolitinib-reduces-acute-gvhd-after-haploidentical-2026a1000tja?src= Longer Targeted Therapy May Not Raise Cancer Risk in SpA Medscape Medical News 4 hours ago Prolonged Targeted Therapy Not Linked to Higher Risk for Cancer in Spondyloarthritis https://www.medscape.com/viewarticle/prolonged-targeted-therapy-not-linked-higher-risk-cancer-2026a1000ti4?src= Cardioprotection Rarely Used in Adults With Blood Cancers Medscape Medical News August 24, 2026 Cardioprotection Rarely Used in Adults With Blood Cancers Edited by Amy Norton https://www.medscape.com/viewarticle/cardioprotection-rarely-used-adults-blood-cancers-2026a1000tcp?src= County-Level Medical Debt Tied to Poorer Cancer Survival Medscape Medical News 59 minutes ago County-Level Medical Debt Tied to Poorer Cancer Survival Edited by Amy Norton https://www.medscape.com/viewarticle/county-level-medical-debt-tied-poorer-cancer-survival-2026a1000tjp?src= How Strong Is Antioxidants’ Link to Cervical Cancer Risk? Medscape Medical News 3 hours ago How Strong Is Antioxidants’ Link to Cervical Cancer Risk? Tara Haelle https://www.medscape.com/viewarticle/how-strong-are-antioxidants-link-cervical-cancer-risk-2026a1000tic?src= Fixed-Duration Combo Shows Promise for Relapsed MCL Medscape Medical News 6 hours ago Fixed-Duration Combo Shows Promise for Relapsed MCL Edited by Gargi Mukherjee https://www.medscape.com/viewarticle/fixed-duration-combo-shows-promise-relapsed-mcl-2026a1000th8?src= Mushrooms Gain Ground in Medicine Despite Limited Evidence Medscape News Europe August 24, 2026 Mushrooms Gain Ground in Medicine Despite Limited Clinical Evidence Laurence Salmon https://www.medscape.com/viewarticle/mushrooms-gain-ground-medicine-despite-limited-clinical-2026a1000tdp?src=

Shaping the Future of Precision Oncology: Biomarker-Driven Care for Tumor-Agnostic Therapies Authors: Benedikt Westphalen, MD, PhD; Vivek Subbiah, MD

https://www.medscape.org/viewarticle/shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk?page=1&src=mkmcmr_driv_stan_mscpedu_260825-OUS-HONC-shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk-cta&uac=148436CN

No calorie counting, no smaller portions: the diet change linked to weight loss ynet|08:19

No calorie counting, no smaller portions: the diet change linked to weight loss A study found that participants on a low-fat vegan diet ate about 491 fewer calories a day and lost an average of 6.4 kg in 16 weeks, without counting calories or cutting portions; so how did it work? ynet|08:19 https://www.ynetnews.com/health_science/article/hyemet9pgg

Trump administration has deleted or altered nearly 400 federal datasets on public health, education and safety standards The Guardian | August 24, 2026

https://geneticliteracyproject.org/2026/08/24/trump-administration-has-deleted-or-altered-nearly-400-federal-datasets-on-public-health-education-and-safety-standards/ America’s official data trove is quietly shrinking, and nobody in charge is explaining why. A Guardian investigation by reporters Amy Qin and Flávio Pessoa found that the Trump administration has deleted at least 28 federal datasets and altered 338 more since January 2025, touching public health, education, and safety records across more than 60 agencies.

Medicine stopped shaking hands. We should start again A brief moment of human connection can make a big difference

https://www.statnews.com/2026/08/24/doctors-hand-shakes-patients-research/ By Zain KhawajaAug. 24, 2026 Khawaja is an emergency medicine resident physician at Northwestern University.

FDA pauses Regenxbio gene therapy trial again due to safety concerns Five patients were found to have small masses on their spines

https://www.statnews.com/2026/08/24/fda-pauses-regenxbio-gene-therapy-trial-hunter-syndrome-safety-concerns/ By Jason MastAug. 24, 2026 General Assignment Reporter

Americans bought 12% less soda under new SNAP restrictions, study says SNAP bans on soda and candy are a major talking point of the Make America Healthy Again movement

https://www.statnews.com/2026/08/24/snap-restrictions-12-percent-drop-soda-purchases/ By Sarah ToddAug. 24, 2026 Reporter, Commercial Determinants of Health

Inside Moderna and Merck’s cancer vaccine triumph The drugmakers overcame rampant doubts, logistical challenges, and the pandemic

https://www.statnews.com/2026/08/24/inside-moderna-and-merck-cancer-vaccine-triumph/ By Matthew Herper, Jason Mast, and Angus ChenAug. 24, 2026

The Next Frontier in Metastatic CRPC: The EZH2 Pathway and Emerging Therapies Authors: Elena Castro, MD, PhD; Michael Schweizer, MD; Neal D. Shore, MD, FACS

https://www.medscape.org/viewarticle/next-frontier-metastatic-crpc-ezh2-pathway-and-emerging-2026a10009uq?page=1&src=mkmcmr_driv_stan_mscpedu_260824-OUS-HONC-next-frontier-metastatic-crpc-ezh2-pathway-and-emerging-2026a10009uq-cta&uac=148436CN

Day 1 - Public Meeting on Listeria monocytogenes Prevention

Day 2 - Public Meeting on Listeria monocytogenes Prevention

Conversations on Cancer: Religious Literacy and Spiritual Care for Patients and Caregivers

Is the Combination of GLP-1s and Clozapine Safe? David Brzostowicki + +++++ +++

https://www.medscape.com/viewarticle/combination-glp-1s-and-clozapine-safe-2026a1000sk0?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986 Patients taking clozapine routinely gain as much as 20 or 30 kg, with weight gain being the most common reason cited for discontinuation of the antipsychotic. Until recently, clinicians had little to offer them. FDA Psychiatry Roundup: Latest Updates https://www.medscape.com/viewarticle/fda-psychiatry-roundup-july-2026-2026a1000qgu?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986 Hidden Health Risks of Borderline Personality Disorder https://www.medscape.com/viewarticle/hidden-health-risks-borderline-personality-disorder-2026a1000ql0?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986 THC Safe, Effective for PTSD-Related Nightmares https://www.medscape.com/viewarticle/thc-safe-effective-ptsd-related-nightmares-2026a1000rc6?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986 No Clear Link Between Semaglutide, Depression https://www.medscape.com/viewarticle/semaglutide-use-and-risk-depression-show-no-clear-2026a1000s4u?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986 Psychiatric Disorders Common in MOGAD https://www.medscape.com/viewarticle/psychiatric-disorders-common-and-emerge-early-mogad-2026a1000s06?ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986 MEDSCAPE AI Clinical questions asked by your peers Which mechanisms drive cardiovascular risk in BPD? https://www.medscape.com/ai-search?query=Which%20mechanisms%20drive%20cardiovascular%20risk%20in%20BPD%3F&ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986 How do cannabinoids affect PTSD nightmare pathophysiology? https://www.medscape.com/ai-search?query=How%20do%20cannabinoids%20affect%20PTSD%20nightmare%20pathophysiology%3F&ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986 Does semaglutide worsen clozapine-related colonic transit delay? https://www.medscape.com/ai-search?query=Does%20semaglutide%20worsen%20clozapine-related%20colonic%20transit%20delay%3F&ecd=mkm_ret_260824_mscpmrk_psych_latest-news_MAI-card_etid8626986&uac=148436CN&impID=8626986

Why ex vivo CAR T still matters in the age of in vivo hype As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable. Written byBree Foster, PhD

Why ex vivo CAR T still matters in the age of in vivo hype As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable. Written byBree Foster, PhD https://www.drugdiscoverynews.com/why-ex-vivo-car-t-still-matters-in-the-age-of-in-vivo-hype-17472 The promise of in vivo CAR T is easy to understand. Instead of removing a patient's cells, engineering them in a manufacturing facility, and returning them to the body, developers are working toward delivering the machinery needed to create CAR T cells directly inside the patient. When a failed trial isn't a failed drug A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment. Written byBree Foster, PhD https://www.drugdiscoverynews.com/when-a-failed-trial-isn-t-a-failed-drug-17431?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--9ymqQTeCqXvQSBNk7-mYIIpdJ6DdkuW3H9ORbkurEIa22v0ufhux8-JXQ-vFQ0uGpbRArvqIeh6orNmzAn-f5FdmOHg&_hsmi=434389976&utm_content=434389976&utm_source=hs_email When a Phase 3 clinical trial misses its primary endpoint, the outcome is often treated as definitive. The drug failed to demonstrate efficacy, development stops, and the therapy may never be tested again. But a negative trial in a heterogeneous patient population does not necessarily mean that every participant failed to benefit. It may instead mean that any treatment effect was diluted when patients with very different disease biology and treatment responses were analyzed together.

Enhancing Clinical Understanding of Oral SERD-Based Therapies for Patients With ER-Positive/HER2-Negative MBC Authors: Nadia Harbeck, MD, PhD; Virginia Kaklamani, MD, DSc; Gregory Vidal, MD, PhD

https://www.medscape.org/viewarticle/enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46?page=1&src=mkmcmr_driv_stan_mscpedu_260823-OUS-HONC-enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46-cta&uac=148436CN

Managing Myeloproliferative Neoplasms: Practice Your Skills in These Virtual Patient Simulations Authors: Claire N. Harrison, DM, FRCP, FRCPath; Haifa Kathrin Al-Ali, MD

https://www.medscape.org/viewarticle/managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o?page=1&src=mkmcmr_driv_psims_mscpedu_260823-OUS-HONC-managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o-cta&uac=148436CN

Bladder Cancer Tumor Board: Optimizing Treatment Selection and Therapeutic Tolerability Authors: Andrea Necchi, MD; Thomas Powles, MBBS, MRCP, MD; Gaia Latini, MSN, RN

https://www.medscape.org/viewarticle/bladder-cancer-tumor-board-optimizing-treatment-selection-2026a1000r3y?page=1

Intensive Nurse-Led Supportive Care Tied to Better QOL During Palliative Chemotherapy Edited by Sayantani Gupta

https://www.medscape.com/viewarticle/intensive-nurse-led-supportive-care-tied-better-qol-during-2026a1000t9k?src= Higher nurse-led supportive care intensity (SCI) was associated with greater improvements in quality of life (QOL), symptom burden, coping, and self-management capability among patients with advanced solid tumors who received palliative chemotherapy.

Breast Cancer Survivors: Who Benefits From Weight-Loss Meds? Will Pass + + + +

https://www.medscape.com/viewarticle/breast-cancer-survivors-who-benefits-weight-loss-meds-2026a1000tdj?src= Preschoolers With Cancer Show Below-Average Motor Function, Muscle Strength at Diagnosis https://www.medscape.com/viewarticle/preschoolers-cancer-show-below-average-motor-function-muscle-2026a1000tcy?src= Preschool children newly diagnosed with cancer demonstrated clinically significant impairments in gross motor function, muscle strength, and functional level. More than three-quarters showed below-average or worse performance in locomotion, and 69% scored below average in functional mobility. Bisphosphonates Tied to Lower Mortality in HR+ Breast Cancer Edited by Katie Lennon https://www.medscape.com/viewarticle/bisphosphonates-tied-lower-mortality-hr-breast-cancer-2026a1000t8b?src= Bisphosphonate (BP) use for at least 1 year after breast cancer diagnosis was associated with reduced all-cause mortality and breast cancer-specific mortality in women with hormone receptor-positive (HR+) breast cancer. Among those with triple-negative breast cancer (TNBC), pre-diagnostic BP use and continued use across both pre- and post-diagnosis periods, on the other hand, were linked to more than tripled recurrence risk and more than doubled breast cancer-specific mortality risk, the new study showed. Does Maintenance Therapy Improve Survival After First-Line Bevacizumab Treatment in Metastatic Colorectal Cancer? Edited by Gargi Mukherjee https://www.medscape.com/viewarticle/does-maintenance-therapy-improve-survival-after-first-line-2026a1000sy8?src= Maintenance therapy was associated with longer overall survival (OS) than active surveillance in patients with metastatic colorectal cancer (mCRC) who achieved disease control after first-line bevacizumab-based combination chemotherapy. However, this association was not maintained after adjustment for baseline prognostic factors, suggesting that baseline differences may have contributed to the observed survival advantage.

Mushrooms Gain Ground in Medicine Despite Limited Clinical Evidence Laurence Salmon

https://www.medscape.com/viewarticle/mushrooms-gain-ground-medicine-despite-limited-clinical-2026a1000tdp?src= Mushrooms have attracted growing interest in nutrition and medicine because their bioactive compounds have anticancer, metabolic, anti-inflammatory, antiviral, neuroprotective, and immunomodulatory effects. However, stronger clinical evidence is required.

Are Microplastics Feeding Cancer Risk? David Brzostowicki

https://www.medscape.com/viewarticle/are-microplastics-feeding-cancer-risk-2026a1000tby Microplastics have been detected in human blood, brain tissue, placentas, and tumors. Federal agencies have committed $144 million to study them. But if patients ask whether microplastics are giving them cancer, the most honest answer may be the least satisfying one: We don’t know, and we’re not close to determining a causal link.

Sharing the Decision of Treatment Planning in High-Risk HR+/HER2- Early Breast Cancer Authors: Shaheenah Dawood, MBBCh, MPH, FACP

https://www.medscape.org/viewarticle/sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67?page=1&src=mkmcmr_driv_32025_mscpedu_452093.39_ace_launch&uac=148436CN

Managing Endometrial Cancer: Unpacking the Data Behind the Latest Immunotherapy Advancements Authors: Ana Oaknin, MD, PhD; Domenica Lorusso, MD, PhD

https://www.medscape.org/viewarticle/managing-endometrial-cancer-unpacking-data-behind-latest-2026a1000bh0?page=1&uac=148436CN&src=mkmcmr_driv_cust_mscpedu_260824-OUS-HONC_NOLO-managing-endometrial-cancer-unpacking-data-behind-latest-2026a1000bh0-cta

Digital program reduces anxiety and depression in adults with chronic medical conditions

https://www.news-medical.net/news/20260820/Digital-program-reduces-anxiety-and-depression-in-adults-with-chronic-medical-conditions.aspx A digital program combining guided movement, breathing and meditation exercises, and coping-skills training reduced anxiety and depression symptoms in adults with chronic medical conditions, according to a new study published August 20th in the open access journal PLOS Medicine by Puneeta Tandon of the University of Alberta, Canada, and colleagues.

Wake-activated brain circuits reveal what drives the urge to sleep

https://www.news-medical.net/news/20260820/Wake-activated-brain-circuits-reveal-what-drives-the-urge-to-sleep.aspx By mapping the brain during prolonged wakefulness, researchers pinpointed neuronal populations whose activity rises with time awake and tested how strongly they shape the pressure to sleep. In a recent study published in the journal Nature, researchers conducted comprehensive whole-brain activity mapping and targeted circuit manipulations in mice to elucidate the poorly understood neural mechanisms governing homeostatic sleep drive.

Multifunctional nanoplatform addresses three key barriers to effective TNBC immunotherapy

https://www.news-medical.net/news/20260821/Multifunctional-nanoplatform-addresses-three-key-barriers-to-effective-TNBC-immunotherapy.aspx Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15-20% of all cases. Unlike other breast cancers, TNBC lacks targetable receptors, leaving patients dependent largely on chemotherapy, with limited treatment options. Even immunotherapy - an approach that has transformed cancer treatment - benefits fewer than 20% of TNBC patients, largely because tumors contain large numbers of regulatory T cells (Tregs) that suppress the immune system and prevent it from effectively attacking cancer cells.

PCOS prevalence rises among pregnant women in China

https://www.news-medical.net/news/20260821/PCOS-prevalence-rises-among-pregnant-women-in-China.aspx Polycystic ovary syndrome (PCOS) affects approximately 6% to 20% of women of reproductive age globally and remains undiagnosed and poorly managed, especially during pregnancy, leading to significant healthcare costs. The economic burden of PCOS was estimated to be $8 billion annually in 2020, with $375 million attributed to pregnancy-related complications. The implementation of China's universal two-child policy has led to an increase in the proportion of advanced-age pregnant women, a greater use of assisted reproductive technologies, and a rise in multiple pregnancy rates, further exacerbating the health risks faced by women with PCOS. However, limited large-scale studies have investigated the prevalence and maternal-fetal outcomes in pregnant women with PCOS. In addition, the impact of China's evolving fertility policies on this population remains largely unclear.

Australian researchers uncover a promising new way to tackle triple-negative breast cancer

https://www.news-medical.net/news/20260821/Australian-researchers-uncover-a-promising-new-way-to-tackle-triple-negative-breast-cancer.aspx Australian researchers have uncovered a promising new way to tackle one of the most aggressive forms of breast cancer, raising hopes for more effective treatments to stop the disease from spreading. The study, undertaken by Adelaide University and the Olivia Newton-John Cancer Research Institute, has identified a molecular switch that drives the spread of triple-negative breast cancer (TNBC) – the subtype responsible for some of the poorest outcomes because it lacks the hormone receptors that make many other breast cancers treatable with existing therapies that target these receptors.

Neurogenesis stalls in the brains of adults with major depressive disorder, study shows

https://www.news-medical.net/news/20260821/Neurogenesis-stalls-in-the-brains-of-adults-with-major-depressive-disorder-study-shows.aspx Most of our brain's 100 billion neurons are created before we're born, but the trickle of neurons created in the adult brain hippocampus could be instrumental in preventing depression, suggest findings from a new study by researchers at Columbia University Vagelos College of Physicians and Surgeons.

Study provides a more nuanced picture of biological mechanisms linked to autism

How does autism manifest in the brain? Researchers from the University of Southern Denmark and Odense University Hospital have investigated this question in a new study involving 60 adults. https://www.news-medical.net/news/20260821/Study-provides-a-more-nuanced-picture-of-biological-mechanisms-linked-to-autism.aspx For the first time, they combined three advanced brain-scanning techniques, allowing them to examine the brain's dopamine system, energy use and communication between brain regions at the same time.

Historic redlining continues limiting healthy food access, study finds

Bad housing, high crime and poor schools are more important than transportation or income when it comes to accessing healthy food in neighborhoods historically subjected to "redlining" - the now-illegal practice once used to refuse loans, insurance or mortgages to people in certain neighborhoods that were disproportionately inhabited by racial and ethnicity minorities. https://www.news-medical.net/news/20260821/Historic-redlining-continues-limiting-healthy-food-access-study-finds.aspx

Only three of 1,357 FDA-cleared AI devices tested patient outcomes

https://www.news-medical.net/news/20260820/Only-three-of-1357-FDA-cleared-AI-devices-tested-patient-outcomes.aspx Hundreds of AI tools are entering clinical care, but researchers traced how quickly the evidence thins out when the focus shifts from regulatory authorization to trials that measure what actually happens to patients. A recent study published in the journal PLOS Digital Health found a significant gap between the number of artificial intelligence (AI)-based medical devices cleared or approved by the United States Food and Drug Administration (US FDA) and the number evaluated for patient outcomes.

GLP-1 Receptor Agonists in Migraine and Intracranial Hypertension: Emerging Off-Label Therapeutic Potential

https://www.news-medical.net/health/GLP-1-Receptor-Agonists-in-Migraine-and-Intracranial-Hypertension-Emerging-Off-Label-Therapeutic-Potential.aspx GLP-1 receptor agonists are emerging as promising investigational therapies for idiopathic intracranial hypertension, with evidence suggesting reductions in intracranial pressure, headache burden, papilledema, and visual complications. Their potential role in primary migraine remains far less certain and requires dedicated randomized clinical trials. Migraine and idiopathic intracranial hypertension (IIH) are distinct neurological conditions, although headache is a major feature of both, and IIH headache frequently has a migraine-like phenotype.1,5,6 The frequent coexistence of obesity and IIH, together with the metabolic actions of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), has led researchers to investigate whether GLP-1 RAs may provide therapeutic benefits beyond weight loss.

Cancer and the Nervous System: Tumor Growth, Metastasis, and Neurobiology

Cancer and the Nervous System: Tumor Growth, Metastasis, and Neurobiology Tumors do more than coexist with nerves; they can recruit, rewire, and exploit neural signaling in ways that reshape growth, immunity, and metastatic spread. Recent evidence shows a complex bidirectional relationship between the nervous system and cancer. This emerging field, known as cancer neuroscience, examines how neurons, neurotransmitters, and neural networks influence tumor initiation, growth, immune regulation, and metastasis, while tumors actively remodel and recruit neural structures to support their progression. These interactions can occur locally within the tumor microenvironment or systemically through neural, neuroendocrine, neuroimmune, and circulating signaling pathways. Understanding these complex interactions has transformed perspectives on tumor biology and identified the nervous system as a promising target for novel cancer therapies. https://www.news-medical.net/health/Cancer-and-the-Nervous-System-Tumor-Growth-Metastasis-and-Neurobiology.aspx

Expanding Xpert MTB/RIF Ultra and lateral flow urine lipoarabinomannan testing for diagnosis of tuberculosis among adults living with HIV admitted to hospitals in Tanzania and Mozambique (EXULTANT): a randomised controlled trial

Expanding Xpert MTB/RIF Ultra and lateral flow urine lipoarabinomannan testing for diagnosis of tuberculosis among adults living with HIV admitted to hospitals in Tanzania and Mozambique (EXULTANT): a randomised controlled trial Marta Cossa, MDa,* ∙ Robert Ndege, PhDb,j,* ∙ Bindiya Meggi, MDc,* ∙ Chacha Mangu, MDd,* ∙ Vinzeigh Leukes, PhDe ∙ Issa Sabi, PhDd ∙ et al. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00133-7/fulltext?dgcid=raven_jbs_etoc_feature_laninf

Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial

Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial Djane C Baía-da-Silva, PhDa,b ∙ Kim Vinícius AmaralC Machado, PhDb,c ∙ Amanda Lia RebêloC Rabelo, MScb,c ∙ Antônio AlcirleyC da Silva Balieiro, PhDa ∙ Antônio S LC Barbosa, BScd ∙ Mônica Regina FariasC Costa, MScd ∙ et al. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00139-8/abstract?dgcid=raven_jbs_etoc_feature_laninf

Oral carbapenem—a double-edged sword? The Lancet Infectious Diseases +...

Oral carbapenem—a double-edged sword? The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/issue/vol26no9/PIIS1473-3099(26)X2008-4

Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial

Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial Prof Fabrice Bonnet, PhDa,b Send email to fabrice.bonnet@chu-bordeaux.fr ∙ Pierre Poulizacc ∙ Nicolas Rousselot, MDd ∙ Prof Thierry Couffinhal, PhDe ∙ Gaël Galli, PhDa,f ∙ Driss Berdaï, MDg ∙ et al. https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00068-1/fulltext?dgcid=raven_jbs_etoc_feature_lanhl

Cognitive behavioural therapy for insomnia and epigenetic ageing: secondary analysis from a randomised controlled trial

Cognitive behavioural therapy for insomnia and epigenetic ageing: secondary analysis from a randomised controlled trial Judith E Carroll, PhDa,b Send email to jcarroll@mednet.ucla.edu ∙ Cynthia D Kusters, MD PhDa,c ∙ Hash Brown Taha, MSd ∙ Prof Richard Olmstead, PhDa,b ∙ Prof Elizabeth C Breen, PhDa,b ∙ Prof Michael R Irwin, MD https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00045-0/fulltext?dgcid=raven_jbs_etoc_feature_lanhl

Ending preventable heat-related deaths among older adults The Lancet Healthy Longevity +...

Ending preventable heat-related deaths among older adults The Lancet Healthy Longevity https://www.thelancet.com/journals/lanhl/issue/vol7no7/PIIS2666-7568(26)X2007-4

Attacks on LGBTQ+ health are a threat to all The Lancet +... + +

Attacks on LGBTQ+ health are a threat to all The Lancet https://www.thelancet.com/journals/lancet/issue/vol408no10556/PIIS0140-6736(26)X2031-1 Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial Dr Marc Ruel, MD MPHa Send email to mruel@ottawaheart.ca ∙ Sathyaki Nambala, MDb ∙ Ming Hao Guo, MD MSca ∙ Alexander Verevkin, MDc ∙ Prem Rabindranauth, MDd ∙ Keita Kikuchi, MD PhDe ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01288-2/abstract?dgcid=raven_jbs_etoc_feature_lancet Risk of transmission of amyloid β pathology via transfused blood products Gargi Banerjee, PhDa ∙ Gustaf Edgren, PhDb ∙ Jingcheng Zhao, MDb ∙ Prof Neil M Ferguson, DPhilc ∙ Prof Heli Harvala, PhDd ∙ James Hope, PhDe ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00767-1/abstract?dgcid=raven_jbs_etoc_feature_lancet

Incidental Fatty Liver on Imaging: What Should You Do Next? Lisa B. VanWagner, MD, MSc; Danielle Brandman, MD, MAS +++ +++

Incidental Fatty Liver on Imaging: What Should You Do Next? Lisa B. VanWagner, MD, MSc; Danielle Brandman, MD, MAS https://www.medscape.com/ca8/p04/podcast-masld-s1-ep3-2026a1000aav?ecd=mkm_mscpapp_260822_mscpmrk_podcasts_etid8615127&uac=148436CN&impID=8615127 Jul 31, 2026 This Week in Cardiology Podcast John M. Mandrola, MD https://www.medscape.com/viewarticle/1003496?ecd=mkm_mscpapp_260822_mscpmrk_podcasts_etid8615127&uac=148436CN&impID=8615127 Common Causes of Vertigo in Primary Care: Part 2 Kevin J. Fernando, MBChB https://www.medscape.com/viewarticle/1003397?ecd=mkm_mscpapp_260822_mscpmrk_podcasts_etid8615127&uac=148436CN&impID=8615127 From Carcinosarcoma to Circulating Tumor DNA: The Importance of Investigator-Initiated Research in Endometrial Cancer Ursula A. Matulonis, MD; Stephanie Lheureux, MD, PhD https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep4-2026a10006ie?ecd=mkm_mscpapp_260822_mscpmrk_podcasts_etid8615127&uac=148436CN&impID=8615127 UTI Vaccines and New Developments in the Treatment of Recurrent UTIs Anne Lenore Ackerman, MD, PhD; J. Curtis Nickel, OC, MD https://www.medscape.com/ca8/p04/podcast-uti-s1-ep1-2026a1000hde?ecd=mkm_mscpapp_260822_mscpmrk_podcasts_etid8615127&uac=148436CN&impID=8615127

Decision-Making for Managing Myelofibrosis-Related Cytopenias: What Is Best Practice? Authors: Paola Guglielmelli, MD, PhD

https://www.medscape.org/viewarticle/decision-making-managing-myelofibrosis-related-cytopenias-2026a1000ar2?page=1&src=mkmcmr_driv_stan_mscpedu_260822-OUS-HONC-decision-making-managing-myelofibrosis-related-cytopenias-2026a1000ar2-cta&uac=148436CN

Researcher, heal thyself: meet the scientists studying their own diseases Studying a condition after being diagnosed with it can be rewarding but also presents some ethical and psychological challenges. By Josie Glausiusz

https://www.nature.com/articles/d41586-026-02455-y?utm_source=Live+Audience&utm_campaign=3600bd2098-nature-briefing-daily-20260821&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Molecular biologist Francesca Granata studies a rare condition called porphyria that can cause burning or itching skin — a path she chose after her own diagnosis in 2008. She and other researchers who study their own rare diseases told Nature that their personal experience with an illness enables them to empathize with other patients, driving them to find better therapies for themselves and others. There is potential bias in studying their own disease, but contributing to an increased understanding of their condition can be deeply fulfilling, they say.

Moderna cancer vaccine stops melanoma returning: what’s next for personalized treatments? Promising trial results suggest cancer vaccines work and could be used to target other tumours. By Rachel Fieldhouse & Mohana Basu

https://www.nature.com/articles/d41586-026-02612-3?utm_source=Live+Audience&utm_campaign=3600bd2098-nature-briefing-daily-20260821&utm_medium=email&utm_term=0_-33f35e09ea-50432164 A personalized mRNA vaccine for melanoma reduced the risk of the cancer returning in a phase III clinical trial, the companies behind the trial announced this week. The vaccine is the first mRNA-based cancer treatment to show success in a late-stage trial, which is “incredibly exciting”, says mRNA researcher Seth Cheetham. The results could have implications beyond the field of cancer, too, says Sam Barrell, the chief executive of medical research charity LifeArc. It could help to build confidence in more-tailored approaches to treatments for rare conditions that are often driven by unique genetic mutations.

Chronic Lymphocytic Leukemia (CLL): Review of Combination Approaches Authors: Jonathon Cohen, MD, MS; Matthew S. Davids, MD, MMSc

https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku?page=1&src=mkmcmr_driv_stan_mscpedu_260819-OUS-HONC-chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku-cta&uac=148436CN

Brain organoid maturation is driven by a lifelike developmental clock Researchers sustained the organoids for nearly six years, potentially unlocking longer term studies of neurodevelopmental disorders.

https://www.nih.gov/news-events/news-releases/brain-organoid-maturation-driven-lifelike-developmental-clock U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institutes of Health For Immediate Release: Wednesday, August 19, 2026 CONTACT: NIH Office of Communications, BRAIN ORGANOID MATURATION IS DRIVEN BY A LIFELIKE DEVELOPMENTAL CLOCK Researchers sustained the organoids for nearly six years, potentially unlocking longer term studies of neurodevelopmental disorders A National Institutes of Health (NIH)-funded scientific team has shown that under the right circumstances, 3D cell culture models of human brain tissue, known as organoids, can express features of later stage brain development. This breakthrough could turn previously unattainable, long-term, benchtop studies of neurodevelopmental disorders into a reality. “The unprecedented longevity and lifelike qualities of these tissue models could afford us the opportunity to dig deeper into how conditions such as autism emerge and unfold later in life,” said Andrea Beckel-Mitchener, Ph.D., acting director of NIH’s National Institute of Mental Health (NIMH). While animal models replicate some key features of human brain development, they are not ideal for studying a process that naturally occurs over nearly two decades. Since it is often not feasible to directly examine this process in humans at a cellular level, researchers have sought to build realistic organoids as alternatives. These models have generally been short-lived, however, only mimicking early development over months in culture. Past attempts have been held back by high batch-to-batch variability as well. A team led by Paola Arlotta, Ph.D., at Harvard University, Cambridge, Massachusetts, previously solved the latter challenge, reporting a method of producing stem-cell derived cerebral cortex organoids of a consistent cellular composition. In this new study, Arlotta and colleagues tested their organoids’ ability to survive and continue to develop over an extended period. During periods in which organoids survived for nearly six years, the researchers tracked the gene expression, biological age, as indicated by chemical alterations to the genome, and structure of organoid cells and with single-cell resolution. They detected the emergence and maturation of neurons as well as their supporting glial cells, with many milestones, including signatures of postnatal development, occurring in the same cadence they would naturally in the human brain. Biological age clocks, which are models trained on real-world human data, demonstrated that their molecular and chronological ages matched, signifying that the organoids developed at a slow, realistic pace, despite being grown outside the context of the body. Neurons also exhibited functional maturity by establishing connections between each other and firing electrical signals that the organoids sustained for at least two years. The authors specifically grew tissue in a fluid that supported this activity, which they suspect was key to their organoids’ neuronal longevity. “The brain doesn’t develop in a vacuum. It’s an organ of incredible complexity that interacts with so many other systems. It was not a given at all that our simplified model would match natural development in this many ways,” said co-first author Irene Faravelli, M.D., Ph.D., who conducted this work as a post-doctoral research fellow at Harvard. To be more certain that what they were seeing was not just circumstantial, the authors transferred neurons from older to younger organoids and then gauged their response to the new environment. Despite receiving signals telling them otherwise, the older cells continued progressing as if they were still housed in their prior organoids, skipping developmental steps compared to their younger neighbors. “I like to think of this as a sort of ‘warping of developmental time’ indicating that the organoid cells record and recall the time they have already spent in culture. This suggests their development is driven by a cell-intrinsic clock, reflecting mechanisms of endogenous human brain development,” said Arlotta. The findings expand on what scientists previously thought was possible for organoids to accomplish and, moving forward, the authors intend to continue pushing the boundaries. Future research could build on this study by aiming to add anatomical complexity to these organoids, simulating developmental disorders, or testing experimental interventions. “There is still much to learn about how the embryo naturally builds a progressively more complex and mature brain,” Arlotta said. “Applying these lessons to organoids will allow us to model unexplored events of human brain maturation that occur after birth.” This research was supported by NIH through NIMH grants RF1MH123977, R01MH112940, RF1MH132710, RF1MH123403, National Institute on Aging (NIA) grants R01AG087374 and R01AG070831, and National Institute of Biomedical Imaging and Bioengineering (NIBIB) grant R01EB024261. About the National Institute of Mental Health (NIMH): The mission of the NIMH is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. For more information, visit the NIMH website. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office --- REFERENCES: Irene Faravelli, Noelia Antón-Bolaños et al. Human brain organoids record the passage of time over multiple years. Nature. August 19, 2026. DOI: 10.1038/s41586-026-10877-x ### This NIH News Release is available online at:

RAS-Targeted Strategies in Pancreatic Cancer: Progress and Future Directions Authors: Brian M. Wolpin, MD, MPH; Eileen M. O’Reilly, MD, FASCO; Zev A. Wainberg, MD

https://www.medscape.org/viewarticle/ras-targeted-strategies-pancreatic-cancer-progress-and-2026a100033c?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260819-OUS-HONC-ras-targeted-strategies-pancreatic-cancer-progress-and-2026a100033c-cta

FDA Approves Multiple Myeloma Drug; FDA Denies Neuroendocrine Drug; Safety Concerns For Prader-W... +++

Rare Endocrine Exchange: Why This Conversation Matters by CheckRare Staff| Published on: Aug 18, 2026

Rare endocrine disorders can be difficult to recognize, challenging to diagnose, and even harder for patients to navigate. For many patients, the journey to an accurate diagnosis can take years. https://checkrare.com/rare-endocrine-exchange-why-this-conversation-matters/

FDA Approves Pasatru (Garetosmab) for Adults With Fibrodysplasia Ossificans Progressiva by Madaline Spencer| Published on: Aug 22, 2026

https://checkrare.com/fda-approves-pasatru-garetosmab-for-adults-with-fibrodysplasia-ossificans-progressiva/

Hilaria Baldwin shares 5 simple stretches to do at work to prevent pain and stiffness +... +...

https://www.foxnews.com/health Waffle House fans divided over unexpected new menu addition: 'That's an absolute no' https://www.foxnews.com/lifestyle?lid=eww9rbevdbnh

Most Read Cancer Science & Oncogenesis +...

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260821

Moderna and Merck say personalized melanoma cancer vaccine worked in late-stage trial FDA approvals and complete responses letters, job cuts, a new FDA commissioner nomination, and more led the news this week. Brought to you byDDN editorial team +++

Moderna and Merck say personalized melanoma cancer vaccine worked in late-stage trial FDA approvals and complete responses letters, job cuts, a new FDA commissioner nomination, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/moderna-and-merck-say-personalized-melanoma-cancer-vaccine-worked-in-late-stage-trial-17470 Moderna’s mRNA cancer vaccine for melanoma coupled with Merck’s prized immunotherapy, Keytruda, successfully reduced the risk of recurrence and metastasis, according to press releases from the companies. No data was shared yet, and the statement says that the results will be presented at an upcoming international meeting. The announcement alone was enough to send shares of Moderna’s stock soaring up to 177 percent on Wednesday as the news ushered in the first time that an mRNA-based cancer vaccine has shown positive results, and the first time that a combination treatment with Keytruda was more efficacious than Keytruda alone. “These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality,” said Stéphane Bancel, CEO of Moderna, in the statement. – Allison Whitten Reengineering cancer vaccines for durable immune memory Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence. Written byBree Foster, PhD https://www.drugdiscoverynews.com/reengineering-cancer-vaccines-for-durable-immune-memory-17293?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8Io-EBMMnsfqcSKrbyQx5kp0RRwlnmPdIO8uAXCuzmOsusockrJx9RuVM1KPjOJ-0luwNayMicB62u3FY41-hk0bVRmw&_hsmi=434324652&utm_content=434324652&utm_source=hs_email When most people think of vaccines, they think of prevention — an injection that trains the immune system to produce antibodies against infectious diseases such as measles or polio. However, cancer vaccines are different. Vaccine generates durable immune responses in people at high risk for pancreatic cancer Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops. Written byAndrea Corona https://www.drugdiscoverynews.com/vaccine-generates-durable-immune-responses-in-people-at-high-risk-for-pancreatic-cancer-17365?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8WL6C0RRNg8xAnFF3JZID8wgD7JGFd3XRpOzB7rdZ6IwrJh7ZHqkj5XjBsCnt_7jL5r7eRTcCpZuWBt33ActpCpvIyZA&_hsmi=434324652&utm_content=434324652&utm_source=hs_email Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest five-year survival rates of any cancer, in large part because it is rarely caught early. Most cases are diagnosed at advanced stages, when surgery is no longer an option and systemic treatment options remain limited. For the roughly 10 percent of cases driven by hereditary predisposition, high-risk individuals are currently managed through surveillance — watching and waiting for signs of transformation into cancer with few tools to intervene before that happens.

Pediatric neurologist Dr. John Gaitanis to lead NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development

https://www.nih.gov/news-events/news-releases/pediatric-neurologist-dr-john-gaitanis-lead-nihs-eunice-kennedy-shriver-national-institute-child-health-human-development U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institutes of Health For Immediate Release: Friday, August 21, 2026 CONTACT: NIH Office of Communications, PEDIATRIC NEUROLOGIST DR. JOHN GAITANIS TO LEAD NIH’S EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT National Institutes of Health (NIH) Director Jay Bhattacharya, M.D., Ph.D., announced the selection of John Gaitanis, M.D., as director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Dr. Gaitanis is set to begin his role on August 23, 2026. As NICHD director, Dr. Gaitanis will shepherd the investment of NICHD’s approximately $1.7 billion annual budget, facilitating research to advance maternal, gynecologic, and child health, as well as the health of people with intellectual and developmental disabilities. He will lead a staff of about 1,100 who either conduct research at NICHD or support some of the institute’s approximately 2,300 research grants and projects at organizations throughout the United States and internationally. “With the burden of chronic disease on the rise, Dr. Gaitanis’s forward-thinking approaches for NICHD research will help us adapt to the realities of today,” Dr. Bhattacharya said. “We’re eager for research advances in prevention, precision, and systems-level understanding to pinpoint root causes of these conditions and yield transformative advances in clinical care to improve health for women, children, and people with disabilities.” Dr. Gaitanis, a nationally respected expert in complex neurodevelopmental disorders, epilepsy, and autism, brings nearly three decades of clinical, academic, and leadership experience to the position. He previously served as Chief of Child Neurology at Tufts Medical Center in Boston, and Director of Child Neurology at Brown Medical School in Providence, Rhode Island. Throughout his distinguished career, Dr. Gaitanis has advanced research and clinical care for individuals with complex neurological and neurodevelopmental conditions, expanded access to specialized services, and trained physicians to deliver comprehensive, individualized care. His work has also advanced clinician education and evidence-informed approaches that support the health, communication needs, autonomy, and dignity of nonspeaking individuals with autism. Dr. Gaitanis received his M.D. from Brown Medical School and completed his pediatrics residency at the University of Rochester. He subsequently completed his neurology training at Boston Children’s Hospital/Harvard Medical School, where he served as chief resident, followed by fellowship training in epilepsy and clinical neurophysiology at Beth Israel Deaconess Medical Center/Harvard Medical School. Dr. Gaitanis previously served on the board of the Epilepsy Foundation of New England and currently serves on the board of the Medical Academy of Pediatrics and Special Needs (MAPS), a national leader in translating emerging science into clinical care for children with severe, chronic, and complex medical conditions. MAPS is home to the only U.S. fellowship program of its kind, providing physicians with advanced training in the application of translational medicine across this highly complex and historically underserved pediatric population. In recognition of his leadership and contributions to the field, Dr. Gaitanis received the MAPS Trailblazer Award in 2025. “I also want to thank Dorothy Fink, M.D., who served as NICHD Acting Director from August 9 during this leadership transition,” Dr. Bhattacharya said. “I appreciate Dr. Fink stepping in to lead the institute during this period.” About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): NICHD leads research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. For more information, visit . About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This NIH News Release is available online at:

Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC Authors: Pasi Jänne, MD, PhD, FASCO; Soo-Ryum (Stewart) Yang, MD; Xiuning Le, MD, PhD

https://www.medscape.org/viewarticle/steps-personalized-and-collaborative-decision-making-her2-2026a10007ur?page=1&src=mkmcmr_driv_stan_mscpedu_260821-OUS-HONC-steps-personalized-and-collaborative-decision-making-her2-2026a10007ur-cta&uac=148436CN

Medical Treatment of Neuroendocrine Tumors (NETs) of the Lung European Scientific Journal ESJ

https://www.academia.edu/172125259/Medical_Treatment_of_Neuroendocrine_Tumors_NETs_of_the_Lung The improvement in histological diagnostic tools, including neuroendocrine markers by immunohistochemistry (IHC), has led to an increased recognition of pulmonary neuroendocrine tumors. This may explain their rapid increase in incidence, representing roughly 30% of all neuroendocrine tumors. NETs represent about 3% of all lung cancers. The incidence of pulmonary NETs is low, although reported to have increased over the past 30 years. According to the surveillance, epidemiology and end results program (SEER) database from 2003, the combined incidence has been 1.57/100 000 inhabitants. The median age at diagnosis for bronchial NETs is 64 years and for thymic NETs 59 years. The main therapy for bronchial NETs is surgical resection. The surgical approach is dependent on the size, location and tissue type. Bronchoscopic laser excision of intraluminal typical bronchial NETs should be considered a suboptimal treatment and reserved for inoperable patients or performed as preoperative disobliterating procedure. Cytotoxic treatment combined with surgical resection when indicated has been the standard for metastatic bronchial and thymic NETs, although the available chemotherapy regimens demonstrate a rather poor effect. Chemotherapy for small-cell lung cancer (SCLC), which is a chemosensitive but not curable cancer, is discussed in the appropriate guidelines.

Sharing the Decision of Treatment Planning in High-Risk HR+/HER2- Early Breast Cancer Authors: Shaheenah Dawood, MBBCh, MPH, FACP

https://www.medscape.org/viewarticle/sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67?page=1&src=mkmcmr_driv_supp_mscpedu_260821&uac=148436CN

Collaborative Excellence in Cancer Care: A Multidisciplinary Approach to Integrating Subcutaneous Immunotherapy Authors: Solange Peters, MD, PhD; Mauricio Burotto, MD; Jürgen E. Gschwend, MD, PhD

https://www.medscape.org/viewarticle/collaborative-excellence-cancer-care-multidisciplinary-2026a1000knq?page=1&src=mkmcmr_driv_stan_mscpedu_260821-OUS-HONC-collaborative-excellence-cancer-care-multidisciplinary-2026a1000knq-cta&uac=148436CN

Immunotherapy Promises New Era in Cancer Prevention

https://www.medscape.com/viewarticle/immunotherapy-promises-new-era-cancer-prevention-2026a1000r9w?ecd=wnl_edit_tpal_etid8621256&uac=148436CN&impID=8621256

Visual Findings of 9 Sexually Transmitted Infections Michael Payette, MD, MBA; Kristen Russomanno, MD

https://reference.medscape.com/p11/visual-findings-9-sexually-transmitted-infections-2026a1000sjv?ecd=wnl_edit_tpal_etid8621256&uac=148436CN&impID=8621256 Sexually transmitted infections (STIs) continue to represent an ongoing US public health crisis, necessitating strong efforts aimed at awareness and prevention. The most up-to-date annual report from the CDC noted "more than 2.5 million cases of syphilis, gonorrhea and chlamydia" diagnosed in the US in 2022.[1] Of new US cases of STIs diagnosed or reported annually, about half of new infections occur among persons aged 15-24 years.